Pathways of colorectal carcinogenesis

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 2, 2013, Pages 97-102

  Arends, Mark J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

adenoma; cancer; colorectal; CpG island methylator phenotype; familial adenomatous polyposis; Lynch; microsatellite instability; mismatch repair

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIN D1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN C JUN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; SMAD4 PROTEIN;

CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME CONDENSATION; COLON ADENOMA; COLON POLYPOSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; COLORECTAL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; DNA REPLICATION; EPIGENETICS; FAMILIAL CANCER; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; INHERITANCE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR PATHOLOGY; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MISMATCH REPAIR; EPIGENESIS, GENETIC; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS;

EID: 84874930240     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/pai.0b013e31827ea79e     Document Type: Conference Paper

References (31)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-170. (Pubitemid 26358996)
3. Barbacid M. Ras genes. Annu Rev Biochem. 1987;56:779-827.
4. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675-684. (Pubitemid 28222141)
5. Naguib A, Wilson CH, Adams DJ, et al. Activation of K-RAS by comutation of codons 19 and 20 is transforming. J Mol Signal. 2011;6:2.
6. Luo F, Brooks DG, Ye H, et al. Conditional expression of mutated K-ras accelerates intestinal tumourigenesis in Msh2-deficient mice. Oncogene. 2007;26:4415-4427. (Pubitemid 47014468)
7. Luo F, Brooks DG, Ye H, et al. Mutated K-rasAsp12 promotes tumourigenesis in ApcMin mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol. 2009;90:558-574.
8. Luo F, Poulogiannis G, Ye H, et al. Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis. Oncol Rep. 2011;26:125-133.
9. Naguib A, Cooke JC, Happerfield L, et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer. 2011;11:123.
10. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
11. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314:268-274. (Pubitemid 44571966)
12. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.
13. Poulogiannis G, Ichimura K, Hamoudi RA, et al. Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol. 2010a;220:338-347.
14. Poulogiannis G, McIntyre R, Dimitriadi M, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U. S. A. 2010b;107:15145-15150.
15. Day E, Poulogiannis G, McCaughan F, et al. Minimal copy regions and expression analyses implicate IRS2 as a candidate driver oncogene in the recurrent 13q34 amplicon in colorectal cancer. Int J Exp Pathol. 2013.
16. Frayling IM. Familial adenomatous polyposis. In: Firth HV, Hirst JA, eds. Oxford Desk Reference-Clinical Genetics. Oxford: Oxford University Press; 2005.
17. Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's two-hit' hypothesis. Nat Med. 1999;5:1071-1075. (Pubitemid 29439582)
18. Frayling IM, Arends MJ. Adenomatous polyposis coli. In: Maloy S, Hughes K, eds. Brenners Encyclopedia of Genetics, Ch 16. 2nd ed. Edinburgh & London, UK: Elsevier; 2012, pp. 1ISBN (In press).
19. Green RA, Kaplan KB. Chromosome instability in colorectal tumor cells is associated with defects in microtubule plus-end attachments caused by a dominant mutation in APC. J Cell Biol. 2003;163:949-961. (Pubitemid 37541872)
20. Arends MJ, Frayling I. Mismatch repair deficiency in hereditary and sporadic colorectal cancer. UK Key Advances in Clinical Practice series: ISBN 1-903044-43-X. Chapter 2. In: Cunningham D, Topham C, Miles A, eds. The Effective Management of Colorectal Cancer. 4th ed. Aesculapius Medical Press: London; 2005:25-40.
21. Toft NJ, Winton DJ, Kelly J, et al. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci USA. 1999;96:3911-3915. (Pubitemid 29169010)
22. Toft NJ, Curtis LJ, Sansom OJ, et al. Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background. Oncogene. 2002;21:6299-6306.
23. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010c;56:167-179.
24. Arends MJ, Ibrahim M, Happerfield L, et al. Interpretation of immunohistochemical analysis of mismatch repair (MMR) protein expression in tissue sections for investigation of suspected Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome. UK NEQAS ICC & ISH Recommendations. 2008.
25. Arends MJ, Frayling I, Happerfield L, Ibrahim M. HNPCC/Lynch Syndrome module: report of the immunohistochemical analysis of mismatch repair (MMR) protein expression. UK NEQAS ICC & ISH Recommendations. 2010.
26. Frayling IM, Happerfield L, Mattocks C, et al. Application of molecular diagnostics to hereditary nonpolyposis colorectal cancer (chapter 32). ISBN: 1-59259-928-1, ISBN13: 978-1-58829-356-5; ISBN10: 1-58829-356-4. In: Coleman WB, Tsongalis GJ, eds. Molecular Diagnostics, For the Clinical Laboratorian. 2nd ed. NJ: Humana Press Inc.; 2005:375-392.
27. Gay L, Arends MJ, Mitrou PN, et al. MLH1 promoter methylation, diet and lifestyle factors in mismatch repair deficient colorectal cancer patients from EPIC-Norfolk. Nutr Cancer. 2011;63:1000-1010.
28. Ahuja N, Li Q, Mohan AL, et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998;58:5489-5494. (Pubitemid 28551135)
29. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681-8686. (Pubitemid 29354851)
30. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787-793. (Pubitemid 43980599)
31. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-130. (Pubitemid 44953403)